Early CMV DNAemia during letermovir prophylaxis predicts lower risk of late CMV infection and is associated with enhanced T-cell immunity after alloHSCT.

Prevymis (letermovir) - Merck (MSD)

Early CMV DNAemia during letermovir prophylaxis predicts lower risk of late CMV infection and is associated with enhanced T-cell immunity after alloHSCT. (PubMed, Sci Rep) - Nov 21, 2025 - "In conclusion, early abortive CMV DNAemia during letermovir prophylaxis appears to induces rapid and durable T-cell immunity. Immune monitoring may not be required in these patients, whereas ELISpot testing at day 100 may guide risk-adapted management in those without early CMV exposure."
Journal • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease • Transplantation • IFNG

http://www.ncbi.nlm.nih.gov/pubmed/41266751

Alexander Sebastian Hölscher; Ben-Niklas Baermann; Duyen Bao Le; Felicitas Schulz; Guido Kobbe; Inga Tometten; Jörg Timm; Kathrin Nachtkamp; Nadine Lübke; Paul Jäger; Sascha Dietrich; Stefanie Munder; Timothé Duplessix

Nov 21, 2025